Loading...
XSTO
SOBI
Market cap8.93bUSD
Apr 07, Last price  
261.80SEK
1D
-4.80%
1Q
-18.49%
Jan 2017
145.36%
IPO
414.80%
Name

Swedish Orphan Biovitrum AB (publ)

Chart & Performance

D1W1MN
P/E
23.14
P/S
3.45
EPS
11.31
Div Yield, %
—
Shrs. gr., 5y
2.30%
Rev. gr., 5y
12.81%
Revenues
26.03b
+17.65%
936,611,0001,201,099,0001,256,425,0001,140,583,0001,296,973,0001,906,700,0001,910,834,0001,923,161,0002,176,694,0002,606,976,0003,227,867,0005,204,340,0006,510,831,0009,138,892,00014,248,000,00015,261,000,00015,529,000,00018,790,000,00022,123,000,00026,027,000,000
Net income
3.89b
+61.27%
176,221,00092,668,00078,984,000-335,361,00032,437,000-104,400,00017,927,000-100,883,000-92,956,000-267,832,00068,393,000809,072,0001,148,612,0002,417,795,0003,304,000,0003,245,000,0002,679,000,0002,638,000,0002,409,000,0003,885,000,000
CFO
7.39b
+65.28%
-65,321,000-87,958,000-25,373,000-506,489,00058,885,000-215,100,000102,930,000405,473,000185,389,000233,770,000507,205,000342,857,0001,332,942,0002,090,276,0003,634,000,0005,214,000,0005,470,000,0004,665,000,0004,470,000,0007,388,000,000
Earnings
Apr 23, 2025

Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
URL
https://www.sobi.com/
IPO date
Sep 15, 2006
Employees
1,793
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
26,027,000
17.65%
22,123,000
17.74%
18,790,000
21.00%
Cost of revenue
20,408,000
17,952,000
14,977,000
Unusual Expense (Income)
NOPBT
5,619,000
4,171,000
3,813,000
NOPBT Margin
21.59%
18.85%
20.29%
Operating Taxes
528,000
546,000
683,000
Tax Rate
9.40%
13.09%
17.91%
NOPAT
5,091,000
3,625,000
3,130,000
Net income
3,885,000
61.27%
2,409,000
-8.68%
2,638,000
-1.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
427,000
6,129,000
89,000
BB yield
-0.39%
-7.04%
-0.13%
Debt
Debt current
4,060,000
8,961,000
5,929,000
Long-term debt
13,077,000
11,840,000
3,505,000
Deferred revenue
Other long-term liabilities
3,172,000
2,861,000
4,146,000
Net debt
15,997,000
19,755,000
7,952,000
Cash flow
Cash from operating activities
7,388,000
4,470,000
4,665,000
CAPEX
(170,000)
(407,000)
(1,477,000)
Cash from investing activities
(3,091,000)
(21,904,000)
(1,477,000)
Cash from financing activities
(4,001,000)
17,012,000
(2,991,000)
FCF
1,983,000
2,863,000
3,281,000
Balance
Cash
1,140,000
904,000
1,361,000
Long term investments
142,000
121,000
Excess cash
542,500
Stockholders' equity
22,128,000
17,315,000
16,314,000
Invested Capital
60,202,000
57,213,000
38,844,500
ROIC
8.67%
7.55%
8.21%
ROCE
8.40%
6.53%
8.83%
EV
Common stock shares outstanding
345,562
325,968
312,455
Price
317.40
18.88%
267.00
23.78%
215.70
16.53%
Market cap
109,681,460
26.02%
87,033,362
29.14%
67,396,595
17.18%
EV
125,687,460
106,788,362
75,348,595
EBITDA
9,298,000
7,340,000
6,232,000
EV/EBITDA
13.52
14.55
12.09
Interest
1,111,000
458,000
Interest/NOPBT
26.64%
12.01%